Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration
The instant invention is directed to methods for treating neurodegenerative diseases comprises administering an effective amount of a selective histone deacetylase 8 inhibitor to a patient in need thereof.
1 . A method of treating a neurodegenerative disease, comprising administering a therapeutically effective amount of a selective HDAC8 inhibitor to a patient in need of such treatment, wherein the selective HDAC8 inhibitor is not (2R)-2-propyloctanoic acid.
2 . The method of claim 1 wherein the HDAC 8 inhibitor is a selective HDAC8 inhibitor which is selective for each of the HDAC1, HDAC3 and HCDAC8 subtypes within a factor of five.
3 . The method of claim 1 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than of less than or equal to 100 PM.
4 . The method of claim 3 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 50 μM.
5 . The method of claim 4 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 25 μM.
6 . The method of claim 5 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 1000 nM.
7 . The method of claim 6 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 500 nM.
8 . The method of claim 7 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 250 nM.
9 . The method of claim 8 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 100 nM.
10 . The method of claim 9 , wherein the HDAC8 inhibitor has an IC 50 for each of HDAC1, HDAC3 and HDAC8 of less than or equal to 50 nM.
11 . The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of vascular dementia, pre-senile and senile dementia, Alzheimer's Disease, multiple sclerosis, amyotrophic lateral sclerosis, Creutzfeldt-Jakob Disease, stroke, traumatic brain injury, spinal cord injury, Pick's disease, Huntington's Disease, progressive supranuclear palsy, Lewy body disease, corticobasal degeneration, Parkinson's Disease, Tourette's Syndrome, familial tremor, torsion dystonia, cerebellar degenerations, spinocerebellar degeneration, Charcot-Marie-Tooth disease, chronic progressive neuropathies, retinitis pigmentosa and hereditary optic atrophy.
12 . The method of claim 11 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's Disease, multiple sclerosis, amyotrophic lateral sclerosis, Creutzfeldt-Jakob Disease, stroke, traumatic brain injury, spinal cord injury, Pick's disease, Huntington's Disease, progressive supranuclear palsy, Lewy body disease and Parkinson's Disease.
13 . The method of claim 12 , wherein the neurodegenerative disease is stroke.
14 . The method of claim 13 , wherein the neurodegenerative disease is ischemic stroke.
15 . A method for identifying one or more compounds useful for treatment of neurodegenerative diseases from a group of compounds, comprising the steps of
(a) assaying the binding affinity of a group of compounds for each of the HDAC1, HDAC3 and HDAC8 subtypes,
(b) determining the IC 50 value for each of the compounds in the group for each of the HDAC1, HDAC3 and HDAC8 subtypes, and
(c) selecting one or more compounds from the group in which the IC 50 value for each of the HDAC1, HDAC3 and HDAC8 subtypes is within a factor of five.
16 . The method of claim 11 , further comprising (d) selecting one or more compounds having an IC 50 value for HDAC8 of less than a threshold value.
17 . The method of claim 12 , wherein the threshold value is selected from the group consisting of 100 μM, 50 μM, 25 μM, 10 μM, 1000 nM, 500 nM, 250 nM, 100 nM and 50 nM.
18 . (canceled)